AXDX — Accelerate Diagnostics Share Price
Last Trade - 00:00- $379.08m
- $461.85m
- $11.34m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.25 | 4.18 | 5.67 | 9.3 | 11.16 | 14.81 | 28.87 | 137.74% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company's in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate PhenoTest BC Kit provides ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit.
Directors
- John Patience CHM (73)
- John Phillips PRE (55)
- Steve Reichling (42)
- Ron Price OTH (57)
- Hany Massarany
- Thomas Brown (73)
- Louise Francesconi (68)
- Mark Miller (65)
- Jack Schuler (80)
- Matthew Strobeck (48)
- Frank Ten Brink (64)
- Charles Watts (78)
- Last Annual
- December 31st, 2020
- Last Interim
- March 31st, 2021
- Incorporated
- December 24th, 2012
- Public Since
- July 24th, 2002
- No. of Shareholders
- 143
- No. of Employees
- 224
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 61,044,021
- Address
- 3950 S. Country Club Road #470, TUCSON, 85714-2240
- Web
- http://acceleratediagnostics.com/
- Phone
- +1 3038638088
- Auditors
- Ernst & Young LLP
Latest News for AXDX
Upcoming events for AXDX
Q3 2021 Accelerate Diagnostics Inc Earnings Release
Similar to AXDX
AETHLON MEDICAL ORD
NASDAQ Capital Market
ALLIED HEALTHCARE PRODUCTS ORD
NASDAQ Capital Market
AXOGEN ORD
NASDAQ Capital Market
BIOLASE ORD
NASDAQ Capital Market
BIONANO GENOMICS ORD
NASDAQ Capital Market
FAQ
As of Today at 19:54 UTC, shares in Accelerate Diagnostics are trading at $6.21. This share price information is delayed by 15 minutes.
Shares in Accelerate Diagnostics last closed at $6.21 and the price had moved by -57.76% over the past 365 days. In terms of relative price strength the Accelerate Diagnostics share price has underperformed the S&P500 Index by -67.95% over the past year.
The overall consensus recommendation for Accelerate Diagnostics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Accelerate Diagnostics does not currently pay a dividend.
Accelerate Diagnostics does not currently pay a dividend.
Accelerate Diagnostics does not currently pay a dividend.
To buy shares in Accelerate Diagnostics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $6.21, shares in Accelerate Diagnostics had a market capitalisation of $379.08m.
Here are the trading details for Accelerate Diagnostics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: AXDX
Based on an overall assessment of its quality, value and momentum Accelerate Diagnostics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Accelerate Diagnostics is $13.00. That is 109.34% above the last closing price of $6.21.
Analysts covering Accelerate Diagnostics currently have a consensus Earnings Per Share (EPS) forecast of -$1.48 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Accelerate Diagnostics. Over the past six months, its share price has underperformed the S&P500 Index by -56.63%.
As of the last closing price of $6.21, shares in Accelerate Diagnostics were trading -26.89% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for Accelerate Diagnostics.
Accelerate Diagnostics' management team is headed by:
- John Patience - CHM
- John Phillips - PRE
- Steve Reichling -
- Ron Price - OTH
- Hany Massarany -
- Thomas Brown -
- Louise Francesconi -
- Mark Miller -
- Jack Schuler -
- Matthew Strobeck -
- Frank Ten Brink -
- Charles Watts -
We do not have data on Accelerate Diagnostics' shareholders